Sabinsa/ Sami Labs welcome FDA inspectors to Indian facilities
Inspectors from the US Food & Drug Administration (FDA) have audited five of Sami Labs (Sabinsa's manufacturing center) facilities in India registered with FDA for dietary ingredient manufacturing.
The FDA inspectors reported no concerns for four of the five facilities, with one 483 observation in the herbal intermediates manufacturing facility. The issue was corrected within days, said Sabinsa, and the compliance report sent to FDA.
“While we would prefer, of course, a perfect inspection report, we remain proud of the quality of our manufacturing facilities,” said Shaheen Majeed, Sabinsa’s marketing director. “We have a dedicated staff that takes great pride in the quality of our facilities.”
The inspected factories are located in Kunigal, Nelamangala, Dobaspet (all in the state of Karnataka), and in Genome Valley in Hyderabad.
